triple agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-16. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Under intense heat, the electrons in the metal ions or small molecules can be excited. These electrons later return to lower energy states, and release light with a colour spectrum characteristic of the species present. In chemical synthesis, salts are often used as precursors for high-temperature solid-state synthesis. Many metals are geologically most abundant as salts within ores. To obtain the elemental materials, these ores are processed by smelting or electrolysis, in which redox reactions occur (often with a reducing agent such as carbon) such that the metal ions gain electrons to become neutral atoms.
=== United Kingdom === Rhodesia was originally a self-governing British crown colony. Although decolonisation in Africa had begun after World War II, it began accelerating in the early 1960s, causing Britain to negotiate independence rapidly with several of its colonies. During this period, it adopted a foreign policy called NIBMAR, or No Independence Before Majority African Rule, mandating democratic reforms that placed governance in the hands of the majority black Africans. The governing white minority of Rhodesia, led by Ian Smith, opposed the policy and its implications. On 11 November 1965, Rhodesia's minority white government made a unilateral declaration of independence (UDI) from the United Kingdom, as it became apparent that negotiations would not lead to independence under the white regime. The United Kingdom government immediately brought in legislation (Southern Rhodesia Act 1965) which formally abolished all Rhodesian government institutions. This move made life difficult for Rhodesian citizens who wished to travel internationally as passports issued by Rhodesia's UDI administration were not recognised as valid; in January 1966, the British issued a statement accepting as valid any passport issued before the declaration of independence and allowing six-month United Kingdom passports to be granted when they expired – provided that the bearer declared they did not intend to aid the UDI Rhodesian government.
Many mixed valence compounds contain both iron(II) and iron(III) centers, such as magnetite and Prussian blue (Fe4[Fe(CN)6]3). The latter is used as the traditional "blue" in blueprints. Iron is the first of the transition metals that cannot reach its group oxidation state of +8, although its heavier congeners ruthenium and osmium can, with ruthenium having more difficulty than osmium. Ruthenium exhibits an aqueous cationic chemistry in its low oxidation states similar to that of iron, but osmium does not, favoring high oxidation states in which it forms anionic complexes. In the second half of the 3d transition series, vertical similarities down the groups compete with the horizontal similarities of iron with its neighbors cobalt and nickel in the periodic table, which are also ferromagnetic at room temperature and share similar chemistry. As such, iron, cobalt, and nickel are sometimes grouped together as the iron triad. Unlike many other metals, iron does not form amalgams with mercury. As a result, mercury is traded in standardized 76 pound flasks (34 kg) made of iron. Iron is by far the most reactive element in its group; it is pyrophoric when finely divided and dissolves easily in dilute acids, giving Fe2+. However, it does not react with concentrated nitric acid and other oxidizing acids due to the formation of an impervious oxide layer, which can nevertheless react with hydrochloric acid. High-purity iron, called electrolytic iron, is considered to be resistant to rust, due to its oxide layer.
== Miscellaneous analysers == Some tests and test categories are unique in their mechanism or scope, and require a separate analyser for only a few tests, or even for only one test. Other tests are esoteric in nature—they are performed less frequently than other tests, and are generally more expensive and time-consuming to perform. Even so, the current shortage of qualified clinical laboratory professionals has spurred manufacturers to develop automated systems for even these rarely performed tests. Analysers that fall into this category include instruments that perform:
Sources: en.wikipedia.org
== Environmental concerns == A large Swedish study shows that it is broken down in wastewater plants and does not release into waterways. A Danish study shows that it biodegrades quickly, but that a risk of continuous leaching from boat paint may cause environmental toxicity.
The tavern serves steak, lamb, venison, duck, and rabbit. In 1956, Cold Spring Tavern was the first restaurant to serve Steve Henson's original salad dressing. Henson and his wife had recently moved to a nearby guest ranch they renamed “Hidden Valley Ranch”, and decided to try marketing the dressing in the area when it became popular with guests. Audrey Ovington, a friend of the Hensons who owned the tavern at the time, was their first commercial customer, and the condiment has since been known as ranch dressing.
CaCO3(s) + CO2(g) + H2O(l) → Ca(HCO3)2(aq) This reaction is important in the erosion of carbonate rock, forming caverns, and leads to hard water in many regions. An unusual form of calcium carbonate is the hexahydrate ikaite, CaCO3·6H2O. Ikaite is stable only below 8 °C.
=== Internal nasal anatomy === In the midline of the nose, the septum is a composite (osseo-cartilaginous) structure that divides the nose into two similar halves. The lateral nasal wall and the paranasal sinuses, the superior concha, the middle concha, and the inferior concha, form the corresponding passages, the superior meatus, the middle meatus, and the inferior meatus, on the lateral nasal wall. The superior meatus is the drainage area for the posterior ethmoid bone cells and the sphenoid sinus; the middle meatus provides drainage for the anterior ethmoid sinuses and for the maxillary and frontal sinuses; and the inferior meatus provides drainage for the nasolacrimal duct. The internal nasal valve comprises the area bounded by the upper lateral-cartilage, the septum, the nasal floor, and the anterior head of the inferior turbinate. In the narrow (leptorrhine) nose, this is the narrowest portion of the nasal airway. Generally, this area requires an angle greater than 15 degrees for unobstructed breathing; for the correction of such narrowness, the width of the nasal valve can be increased with spreader grafts and flaring sutures.
== Nutrition == Over the years, there has been controversy as to whether frozen vegetables are better or worse than fresh ones. Generally, reports show that frozen vegetables are as nutritionally beneficial when compared to fresh ones. In general, boiling vegetables can cause them to lose vitamins. Thus, the process of blanching does have deleterious effects on some nutrients. In particular, vitamin C and folic acid are susceptible to loss during the commercial process. That said, any additional loss from blanching and freezing is insignificant compared to the loss from direct boiling: when compared to fresh raw vegetables, boiled fresh vegetables shows as much loss of nutrients as boiled frozen vegetables. In addition, studies have shown that thawing frozen vegetables before cooking can accelerate the loss of vitamin C. A 1997 study performed by the University of Illinois, 2007 study performed by University of California – Davis and a 2003 Austrian study support that canned or frozen produce has no substantial nutritional difference not attributable to the presence of added salt, syrup or other flavouring. In fact, these studies suggest that canned or frozen produce is nutritionally superior because of the very rapid deterioration of nutrients in fresh produce. A 2014 study which looks at both nutrition and cost provides the same conclusion about nutrition, but also that canned vegetables are consistently cheaper than frozen and fresh vegetables.
Sources: en.wikipedia.org
In 2009, the first to obtain FDA approval for topical DMSO usage was PENNSAID, which contains diclofenac in a carrier with 45.5% DMSO Each 1 mL of TDiclo contains 16.05 mg diclofenac sodium. TDiclo solution also contains 45.5% dimethyl sulfoxide (DMSO) vehicle, which can result in enhanced penetration of active drug through the skin. The most common adverse event reported was dry skin at the application site (25.3% of patients), followed by contact dermatitis (13.0%)In interventional radiology, DMSO is used as a solvent for ethylene vinyl alcohol in the Onyx liquid embolic agent, which is used in embolization, the therapeutic occlusion of blood vessels. In cryobiology DMSO has been used as a cryoprotectant and is still an important constituent of cryoprotectant vitrification mixtures used to preserve organs, tissues, and cell suspensions. Without it, up to 90% of frozen cells will become inactive. It is particularly important in the freezing and long-term storage of embryonic stem cells and hematopoietic stem cells, which are often frozen in a mixture of 10% DMSO, a freezing medium, and 30% fetal bovine serum. In the cryogenic freezing of heteroploid cell lines (MDCK, VERO, etc.) a mixture of 10% DMSO with 90% EMEM (70% EMEM + 30% fetal bovine serum + antibiotic mixture) is used. As part of an autologous bone marrow transplant the DMSO is re-infused along with the patient's own hematopoietic stem cells. DMSO is metabolized by disproportionation to dimethyl sulfide and dimethyl sulfone. It is subject to renal and pulmonary excretion.
Insulin shock therapy or insulin coma therapy was a form of psychiatric treatment in which patients were repeatedly injected with large doses of insulin in order to produce daily comas over several weeks. It was introduced in 1927 by Austrian-American psychiatrist Manfred Sakel and used extensively in the 1940s and 1950s, mainly for schizophrenia, before falling out of favour and being replaced by neuroleptic drugs in the 1960s. It was one of a number of physical treatments introduced into psychiatry in the first four decades of the 20th century. These included the convulsive therapies (cardiazol/metrazol therapy and electroconvulsive therapy), deep sleep therapy, and psychosurgery. Insulin coma therapy and the convulsive therapies are collectively known as the shock therapies.
=== Contestants === 1st - Jasmin Bell, Pastry Instructor from Seattle, Washington 2nd - Jonathan Elias, Pastry Chef from Troy, Michigan 3rd - Jessica Scott, Executive Pastry Chef from San Diego, California 4th - Ray Vizcaino, Cake Decorator from San Diego, California 5th - Tyler Davis, Pastry Chef from St. Louis, Missouri 6th - Dina Melendez, Pastry Chef from Brooklyn, New York 7th - Cliff Butler, Pastry Chef from Austin, Texas 8th - Andrea Kratville, Home Baker from Sonora, California
==== Ghana ==== In 2018, Zipline signed a contract with the government of Ghana to make up to 600 deliveries a day for four years at the cost of about $12.5 million. In April 2019, Ghana's president Nana Akufo-Addo announced the opening of the first distribution center in Ghana. Vice President Mahamudu Bawumia launched the first Zipline drone to Tafo Hospital on April 24, 2019. This first delivery contained a resupply shipment of yellow fever vaccines to prevent stock-out. In 2021, the government of Ghana expanded its contract with Zipline to add four additional distribution centers, bringing the total number of contracted distribution centers in the country to eight. Zipline presently operates six distribution centers in Ghana, serving over 2,300 health facilities. When the network is complete, Zipline will be able to serve about 85 percent of the population directly and the remainder indirectly, reaching over 3,200 health facilities in every region of the country. In March 2022, Zipline announced that the company had delivered over one million doses of the COVID-19 vaccine by drone in Ghana over the prior year. An independent study of Zipline's impact on the health system in Ghana found that Zipline's drone delivery service shortened vaccine stock-outs by 60 percent, decreased inventory-driven missed vaccination opportunities by 42 percent, decreased days facilities were without critical medical supplies by 21 percent, and increased the types of medicines and supplies stocked at health facilities by 10 percent.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.